Barclays Raises Humana (HUM) Price Target to $582

Barclays has reaffirmed its Overweight rating on Humana, raising the price target to $582, a 39.11% upside from the current price.

By EarningsIQ Research Desk · Published Oct 16, 2026, 2:08 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Barclays raised its price target on Humana Inc. ($HUM) to $582 from $515 on October 9, 2026, and rates the stock "Overweight".

Since the rating, $HUM is down 4.3% after 1 week and down 4.3% to date (from the $431.87 close on Oct 9, 2026).

HUM Humana Inc.

$413.16 +57.38% year to date

Daily close · Oct 16, 2026

Key Points

On October 9, 2026, Barclays reiterated its Overweight rating on Humana Inc. (NYSE: HUM) with a new price target of $582, up from $515.
Barclays's $582 price target implies 39.11% upside from Humana Inc.'s ($HUM) current $418.36 share price.
As of October 16, 2026, Humana shares are trading at $418.36, which is 28.1% below Barclays' target and 10.1% below the mean analyst price target of $465.13.
Humana reported a revenue of $145.7 billion over the trailing twelve months, with a net margin of 0.9% and a P/E ratio of 39.7.

Get $HUM trade alerts by text

We text you when insiders, Congress or big funds trade $HUM. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Humana Inc. alert may contain errors. Disclosures

Barclays has reiterated its Overweight rating on Humana Inc. (NYSE: HUM) on October 9, 2026, raising the price target to $582 from a prior target of $515. This suggests a positive outlook for the healthcare company's stock despite current trading levels.

Humana Inc. Stock Down 2.1%

As of October 16, 2026, Humana shares are trading at $418.36. This price is 28.1% below Barclays' new target and 10.1% below the mean analyst price target of $465.13. The stock is currently above its 50-day moving average by 6.5% and significantly above its 200-day moving average by 39.3%. However, it is 8.4% below its 52-week high of $456.50.

12-month forecast

$HUM price target

Humana Inc. daily closes and this analyst's $582 target. Not advice.

Other Institutional Activity in Humana

Dodge & Cox Inc. reduced its holdings by 440,438 shares, bringing its total to 10,940,380 shares valued at about $4.5 billion. Blackrock Inc. increased its stake by 218,270 shares, totaling 10,417,803 shares worth approximately $4.3 billion. Vanguard Capital Management LLC added 4,703 shares, ending with 7,843,620 shares valued at about $3.2 billion. Vanguard Portfolio Management LLC slightly increased its position by 10,455 shares, holding 5,818,956 shares valued at around $2.4 billion. State Street Corporation also grew its holdings by 3,817 shares, totaling 5,457,072 shares worth about $2.3 billion.

Recent Earnings

Humana's revenue for the trailing twelve months reached $145.7 billion, reflecting a year-over-year growth of 26.2%. The company reported a net margin of 0.9% and a return on equity of 6.9%. The next earnings report is expected on November 6, 2026.

Insider Buying and Selling at Humana Inc.

On February 23, 2026, Sanjay K. Shetty, an officer at Humana, bought 810 shares at an average price of $185.20, totaling about $150,016. This purchase reflects confidence in the company's future performance.

Analysts Set New Price Targets

On October 9, 2026, Barclays maintained its Overweight rating on Humana with a new price target of $582. Oppenheimer also maintained its Outperform rating, raising its target to $475 from $405. Baird upgraded its rating to Outperform, setting a target of $596, up from $390. UBS maintained its Neutral rating with a target of $495, while Truist Securities kept its Hold rating with a target of $475, up from $415.

About Humana Inc.

Humana Inc. provides medical and specialty insurance products across the United States, operating primarily in two segments: Insurance and CenterWell. The company has a strong market presence in the healthcare sector, which continues to grow.

Bottom Line

Investors should watch for Humana's next earnings report on November 6, 2026, to gauge its financial health and market response. With Barclays' recent rating and target adjustment, the stock's performance relative to analyst expectations will be key.